Cargando…

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Jae Young, Kim, Byung Seok, Lee, Chang Hyeong, Song, Jeong Eun, Lee, Heon Ju, Park, Jung Gil, Hwang, Jae Seok, Chung, Woo Jin, Jang, Byoung Kuk, Kweon, Young Oh, Tak, Won Young, Park, Soo Young, Jang, Se Young, Suh, Jeong Ill, Kwak, Sang Gyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610199/ https://www.ncbi.nlm.nih.gov/pubmed/29792020 http://dx.doi.org/10.3904/kjim.2017.368

Ejemplares similares

Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites
por: Lee, Jin Wook, et al.
Publicado: (2021)

Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment
por: Song, Jeong Eun, et al.
Publicado: (2021)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
por: Lee, Byung Seok, et al.
Publicado: (2019)

Changes in Characteristics of Patients with Liver Cirrhosis Visiting a Tertiary Hospital over 15 Years: a Retrospective Multi-Center Study in Korea
por: Jang, Won Young, et al.
Publicado: (2020)

Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea
por: Lee, Yu Rim, et al.
Publicado: (2020)

Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study
por: Park, Jung Gil, et al.
Publicado: (2020)

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
por: Cho, Byeong Wook, et al.
Publicado: (2017)

Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort study
por: Park, Jung Gil, et al.
Publicado: (2017)

Effects of Branched-Chain Amino Acid (BCAA) Supplementation on the Progression of Advanced Liver Disease: A Korean Nationwide, Multicenter, Prospective, Observational, Cohort Study
por: Park, Jung Gil, et al.
Publicado: (2020)

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
por: Lee, Hye Won, et al.
Publicado: (2018)

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
por: Taki, Shinya, et al.
Publicado: (2018)

Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients
por: Tarao, Kazuo, et al.
Publicado: (2017)

Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir
por: Baba, Hayato, et al.
Publicado: (2016)

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
por: Yoon, Jae-Hyun, et al.
Publicado: (2023)

Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis
por: Lee, Jung Min, et al.
Publicado: (2016)

Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
por: Kumada, Hiromitsu, et al.
Publicado: (2014)

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions
por: Fujii, Hideki, et al.
Publicado: (2017)

A case with acute-on-chronic liver failure receiving liver transplantation during daclatasvir and asunaprevir therapy in chronic hepatitis C patient
por: Park, Wonhyeong, et al.
Publicado: (2018)

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
por: Nam, Hee Chul, et al.
Publicado: (2016)

Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
por: de Ruiter, Petra E, et al.
Publicado: (2018)

Clinical significance of lncRNA-ATB expression in human hepatocellular carcinoma
por: Jang, Se Young, et al.
Publicado: (2017)

Effect of switching from nucleos(t)ide maintenance therapy to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomized trial
por: Woo, Hyun Young, et al.
Publicado: (2022)

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
por: Osawa, Mayu, et al.
Publicado: (2018)

Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study
por: Shin, Seung Kak, et al.
Publicado: (2019)

Long interspersed nuclear element-1 hypomethylation is associated with poor outcomes via the activation of ST18 in human hepatocellular carcinoma
por: Lee, Yu Rim, et al.
Publicado: (2021)

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions
por: Miyashima, Yuichi, et al.
Publicado: (2016)

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection
por: Otsuka, Taiga, et al.
Publicado: (2017)

Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
por: Ueno, Takayo, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection
por: Osawa, Mayu, et al.
Publicado: (2018)

Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir
por: Sugiura, Ayumi, et al.
Publicado: (2017)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
por: Itakura, Jun, et al.
Publicado: (2016)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
por: Wei, Lai, et al.
Publicado: (2018)

Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life
por: Kawakubo, Megumi, et al.
Publicado: (2018)

Daclatasvir and asunaprevir improves health‐related quality of life in Japanese patients infected with hepatitis C virus
por: Ikeda, Hiroki, et al.
Publicado: (2018)

Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
por: Fujii, Hideki, et al.
Publicado: (2022)

Kahweol Ameliorates the Liver Inflammation through the Inhibition of NF-κB and STAT3 Activation in Primary Kupffer Cells and Primary Hepatocytes
por: Seo, Hye-Young, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_igg145mqn3irqgc3gucdts9ei7